Pharmakotherapie bei erektiler Dysfunktion

Die erektile Dysfunktion (ED) ist die häufigste sexuelle Funktionsstörung des Mannes. Sie ist definiert als persistierendes Unvermögen, Erektionen erreichen oder aufrechterhalten zu können. Die verschiedenen Schweregrade reichen von mild bis schwer, sie werden durch den International Index of Erectile Function Index (IIEF) klassifiziert ([Hatzimouratidis et al. 2010] ). Mit Einführung der Phosphodiesterase-5-Hemmer (PDE5-Hemmer) wurde die medikamentöse ED-Therapie effektiver, einfacher und nebenwirkungsärmer. Dieser Übersichtsartikel gibt eine kurze Einführung in die Grundlagen der ED und erläutert Indikationen und Optionen bei der medikamentösen Therapie.

• Literatur

• Afif-Abdo J, Teloken C, Damiao R et al. Comparative Cross-Over Study of Sildenafil and Apomorphine for Treating Erectile Dysfunction. BJU Int 2008; 102: 829-834
• Althof SE.. Quality of Life and Erectile Dysfunction. Urology 2002; 59: 803-810
• Bechara A, Casabé A, De Bonis W et al. Recreational Use of Phosphodiesterase Type 5 Inhibitors by Healthy Young Men. J Sex Med 2010; 7: 3736-3742
• Braun M, Wassmer G, Klotz T et al. Epidemiology of Erectile Dysfunction: Results of the ‚Cologne Male Survey‘. Int J Impot Res 2000; 12: 305-311
• Briganti A, Chun FK, Salonia A et al. A Comparative Review of Apomorphine Formulations for Erectile Dysfunction: Recommendations for Use in the Elderly. Drugs Aging 2006; 23: 309-319
• Chughtai B, Lee RK, Te AE, Kaplan SA. Metabolic Syndrome and sexual Dysfunction. Curr Opin Urol 2011; 21: 514-518
• Corona G, Mondaini N, Ungar A et al. Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction: The Proper Drug for the Proper Patient. J Sex Med 2011; 8: 3418-3432
• Dhir RR, Lin HC, Canfield SE, Wang R. Combination Therapy for Erectile Dysfunction: An Update Review. Asian J Androl 2011; 13: 382-390
• Ding H, Du W, Wang H et al. Efficacy and Safety of Udenafil for Erectile Dysfunction: A Meta-Analysis of Randomized Controlled Trials. Urology 2012; 80: 134-139
• Donatucci CF, Wong DG, Giuliano F et al. Efficacy and Safety of Tadalafil Once Daily: Considerations for the Practical Application of a Daily Dosing Option. Curr Med Res Opin 2008; 24: 3383-3392
• Esposito K, Ciotola M, Giugliano F et al. Effects of Intensive LifeStyle Changes on Erectile Dysfunction in Men. J Sex Med 2009; 6: 243-250
• Hatzimouratidis K, Amar E, Eardley I et al. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. Europ Urol 2010; 57: 804-814
• Jackson G, Boon N, Eardley I et al. Erectile Dysfunction and Coronary Artery Disease Prediction: Evidence-Based Guidance and Consensus. Int J Clin Pract 2010; 64: 848-857
• Korkes F, Costa-Matos A, Gasperini R et al. Recreational Use of PDE5 Inhibitors by Young Healthy Men: Recognizing this Issue among Medical Students. J Sex Med 2008; 5: 2414-2418
• Kumar R, Nehra A. Central Nervous System Agents and Erectile Dysfunction. Urol Clin North Am 2011; 38: 165-173
• Laumann EO, Paik A, Rosen RC. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA 1999; 281: 537-544
• McMahon C. Comparison of Efficacy, Safety, and Tolerability of On-Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile Dysfunction. J Sex Med 2005; 2: 415-425 discussion 425–417
• Melnik T, Soares BG, Nasselo AG. Psychosocial Interventions for Erectile Dysfunction. Cochrane Database Syst Rev 2007; 18 CD004825
• Melnik T, Soares BG, Nasello AG. The Effectiveness of Psychological Interventions for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis, Including Comparisons to Sildenafil Treatment, Intracavernosal Injection, and vacuum Devices. J Sex Med 2008; 5: 2562-2574
• Phe V, Roupret M. Erectile Dysfunction and Diabetes: A Review of the Current Evidence-Based Medicine and a Synthesis of the Main Available Therapies. Diabetes Metab 2012; 38: 1-13
• Park HJ, Choi HK, Ahn TY et al. Efficacy and Safety of Oral Mirodenafil in the Treatment of Erectile Dysfunction in Diabetic Men in Korea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled clinical Trial. J Sex Med 2010; 7: 2842-2850
• Porst H, Hell-Momeni K, Büttner H. Chronische PDE-5-Hemmung bei erektiler Dysfunktion. Urologe 2009; 48: 1318-1329
• Segal R, Burnett AL. Avanafil for the Treatment of Erectile DysFunction. Drugs Today (Barc) 2012; 48: 7-15
• Tsertsvadze A, Fink HA, Yazdi F et al. Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-Analysis. Ann Intern Medicine 2009; 151: 650-661
• Ude M, Ude C, Leuner K. Nitrate und PDE5-Hemmer: Pharmazeutische Betreuung. Therapiebegleitende Beratung in der Apotheke. Pharmazie in unserer Zeit 2010; 39: 397-404
• Washington SL, Shindel AW. A Once-Daily Dose of Tadalafil for Erectile Dysfunction: Compliance and Efficacy. Drug Des Devel Ther 2010; 4: 159-171
• Zhang X, Feng Q, Cote RH. Efficacy and Selectivity of Phosphodiesterase-Targeted Drugs in Inhibiting Photoreceptor Phosphodiesterase (PDE6) in Retinal Photoreceptors. Invest Ophthalmol Vis Sci 2005; 46: 3060-3066